Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 24, 2013Wed, January 23, 2013Tue, January 22, 2013Mon, January 21, 2013Fri, January 18, 2013Thu, January 17, 2013Wed, January 16, 2013Tue, January 15, 2013Mon, January 14, 2013Fri, January 11, 2013Thu, January 10, 2013Wed, January 9, 2013Tue, January 8, 2013Mon, January 7, 2013Sun, January 6, 2013Fri, January 4, 2013Thu, January 3, 2013Wed, January 2, 2013Mon, December 31, 2012Fri, December 28, 2012Thu, December 27, 2012Wed, December 26, 2012Mon, December 24, 2012Fri, December 21, 2012Thu, December 20, 2012Levi &;; Korsinsky Notifies Investors With Losses on Their Investment in Abiomed, Inc. of Class Action Lawsuit and th
Published in Health and Fitness on Tuesday, January 8th 2013 at 15:00 GMT by Market Wire
January 08, 2013 17:48 ET
UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Abiomed, Inc. of Class Action Lawsuit and the Deadline of January 15, 2013 to Seek a Lead Plaintiff Position
NEW YORK, NY--(Marketwire - Jan 8, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Abiomed, Inc. ("Abiomed" or the "Company") (
For more information, click here: [ http://zlk.9nl.com/abiomed-abmd ].
The complaint alleges that, throughout the Class Period, Abiomed made materially misleading statements regarding the Company's financial strength and prospects. In particular, it is alleged that positive statements concerning the Company were misleading because the United States Food and Drug Administration ("FDA") repeatedly warned Abiomed that its promotional materials contained inappropriate claims regarding its Impella 2.5 catheter and suggested improper off-label uses. Abiomed repeatedly assured investors that they had addressed the FDA's concerns and that the matter was resolved.
On November 1, 2012, Abiomed disclosed that the Department of Justice had initiated an investigation "focused on the Company's marketing and labeling of the Impella 2.5." On this news, shares of Abiomed's stock fell from $19.82 per share on October 31, 2012 to close at $13.61 on November 1, 2012.
If you suffered a loss in Abiomed you have until January 15, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://zlk.9nl.com/abiomed-abmd ].
Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
